Your browser doesn't support javascript.
loading
Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of treatment-naïve patients with pancreatic ductal adenocarcinoma.
Permuth, Jennifer B; Park, Margaret A; Chen, Dung-Tsa; Basinski, Toni; Powers, Benjamin D; Gwede, Clement K; Dezsi, Kaleena B; Gomez, Maria; Vyas, Shraddha L; Biachi, Tiago; Cortizas, Elena M; Crowder, Sylvia; Genilo-Delgado, Maria; Green, B Lee; Greene, Anna; Gregg, Christopher; Hoffe, Sarah E; Jiang, Kun; Kim, Bora; Vasudevan, Vanitha; Garcialopez De Llano, Jeronimo; Menon, Anjana A; Mo, Qianxing; MorenoUrazan, Lina M; Mok, Shaffer; Parker, Nathan; Rajasekhara, Sahana; Rasool, Ghulam; Sinnamon, Andrew; Sparks, Lauren; Stewart, Paul A; Tardif, Kenneth; Tassielli, Alexandra F; Teer, Jamie K; Tran, Dan Viet; Turner, Kea L; Vadaparampil, Susan T; Whelan, Christopher J; Douglas, Wade G; Velanovich, Vic; Karachristos, Andreas; Legaspi, Adrian; Meredith, Kenneth; Molina-Vega, Manual A; Huguet, Kevin L; Arnoletti, Juan P; Bloomston, Mark; Trevino, Jose; Merchant, Nipun B; Pimiento, Jose M.
Afiliación
  • Permuth JB; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.
  • Park MA; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Chen DT; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Basinski T; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States.
  • Powers BD; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States.
  • Gwede CK; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Dezsi KB; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Gomez M; Department of Surgery, School of Medicine, University of Maryland, Baltimore, MD, United States.
  • Vyas SL; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
  • Biachi T; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.
  • Cortizas EM; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.
  • Crowder S; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Genilo-Delgado M; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.
  • Green BL; Research Analytics and Development Cores, Baylor Scott & White Research Institute (BSWRI), Dallas, TX, United States.
  • Greene A; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Gregg C; Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
  • Hoffe SE; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
  • Jiang K; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Kim B; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
  • Vasudevan V; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States.
  • Garcialopez De Llano J; Department of Neurobiology, School of Medicine, University of Utah Health, Salt Lake City, UT, United States.
  • Menon AA; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Mo Q; Department of Pathology, Moffitt Cancer Center, Tampa, FL, United States.
  • MorenoUrazan LM; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Mok S; Center for Advanced Surgical Oncology, Palmetto General Hospital, Hialeah, FL, United States.
  • Parker N; Center for Advanced Surgical Oncology, Palmetto General Hospital, Hialeah, FL, United States.
  • Rajasekhara S; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Rasool G; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States.
  • Sinnamon A; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Sparks L; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Stewart PA; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
  • Tardif K; Supportive Care Medicine, Moffitt Cancer Center, Tampa, FL, United States.
  • Tassielli AF; Department of Machine Learning, Moffitt Cancer Center, Tampa, FL, United States.
  • Teer JK; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
  • Tran DV; Translational Research Institute, AdventHealth, Orlando, FL, United States.
  • Turner KL; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States.
  • Vadaparampil ST; Department of Surgery, St. Anthony's Hospital, St. Petersburg, FL, United States.
  • Whelan CJ; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
  • Douglas WG; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States.
  • Velanovich V; Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
  • Karachristos A; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
  • Legaspi A; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
  • Meredith K; Community Outreach, Engagement & Equity, Moffitt Cancer Center, Tampa, FL, United States.
  • Molina-Vega MA; Department of Metabolism and Cancer Physiology, Moffitt Cancer Center, Tampa, FL, United States.
  • Huguet KL; Department of Clinical Sciences, College of Medicine, Florida State University, Tallahassee, FL, United States.
  • Arnoletti JP; Tampa General Hospital, Tampa, FL, United States.
  • Bloomston M; Tampa General Hospital, Tampa, FL, United States.
  • Trevino J; Center for Advanced Surgical Oncology, Palmetto General Hospital, Hialeah, FL, United States.
  • Merchant NB; Department of Gastrointestinal Surgical Oncology, Sarasota Memorial Hospital, Sarasota, FL, United States.
  • Pimiento JM; Department of Surgical Oncology, Lakeland Regional Hospital, Lakeland, FL, United States.
Front Oncol ; 14: 1362244, 2024.
Article en En | MEDLINE | ID: mdl-39109281
ABSTRACT

Introduction:

Cancer-associated cachexia (CC) is a progressive syndrome characterized by unintentional weight loss, muscle atrophy, fatigue, and poor outcomes that affects most patients with pancreatic ductal adenocarcinoma (PDAC). The ability to identify and classify CC stage along its continuum early in the disease process is challenging but critical for management.

Objectives:

The main objective of this study was to determine the prevalence of CC stage overall and by sex and race and ethnicity among treatment-naïve PDAC cases using clinical, nutritional, and functional criteria. Secondary objectives included identifying the prevalence and predictors of higher symptom burden, supportive care needs, and quality of life (QoL), and examining their influence on overall survival (OS). Materials and

methods:

A population-based multi-institutional prospective cohort study of patients with PDAC was conducted between 2018 and 2021 by the Florida Pancreas Collaborative. Leveraging patient-reported data and laboratory values, participants were classified at baseline into four stages [non-cachexia (NCa), pre-cachexia (PCa), cachexia (Ca), and refractory cachexia (RCa)]. Multivariate regression, Kaplan Meier analyses, and Cox regression were conducted to evaluate associations.

Results:

CC stage was estimated for 309 PDAC cases (156 females, 153 males). The overall prevalence of NCa, PCa, Ca, and RCa was 12.9%, 24.6%, 54.1%, and 8.4%, respectively. CC prevalence across all CC stages was highest for males and racial and ethnic minorities. Criteria differentiated NCa cases from other groups, but did not distinguish PCa from Ca. The most frequently reported symptoms included weight loss, fatigue, pain, anxiety, and depression, with pain significantly worsening over time. The greatest supportive care needs included emotional and physical domains. Males, Black people, and those with RCa had the worst OS.

Conclusions:

Using clinical, nutritional, and functional criteria, nearly one-quarter of the PDAC cases in our diverse, multi-institutional cohort had PCa and 62.5% had Ca or RCa at the time of diagnosis. The PCa estimate is higher than that reported in prior studies. We recommend these criteria be used to aid in CC classification, monitoring, and management of all incident PDAC cases. Findings also highlight the recommendation for continued emotional support, assistance in alleviating pain, and supportive care needs throughout the PDAC treatment journey.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza